B. Riley Downgrades Cassava Sciences to Neutral From Buy, Notes Challenging Near-Term Catalyst Profile, Prolonged Litigation Mess; Maintains $44 PT – Marketscreener.com

Leave a Reply

Your email address will not be published. Required fields are marked *